Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 17/20 | 1.00 |
| ▸ | ESR1 | P03372 | 15/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286186 | 0.70 | ESR1 (1.00) | ESR2ESR1HSD17B10 | |
| SCHEMBL12009549 | 0.64 | ESR1 (0.52) | ESR2ESR1HSD17B10KDM4ETSHR | |
| SCHEMBL8711307 | 0.64 | ESR1 (0.47) | ESR2ESR1HSD17B10KDM4ETSHR | |
| SCHEMBL6283932 | 0.64 | ESR1 (1.00) | ESR2ESR1HSD17B10KDM4ETSHR | |
| SCHEMBL6282610 | 0.64 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL6794599 | 0.63 | ESR2 (0.49) | ESR2ESR1 | |
| SCHEMBL6286195 | 0.62 | ESR1 (1.00) | ESR2ESR1HSD17B10KDM4ETSHR | |
| SCHEMBL6794055 | 0.62 | ESR1 (0.44) | ESR2ESR1ALDH1A1MAPTRAB9A | |
| SCHEMBL697437 | 0.61 | ALOX5 (0.47) | ESR2ESR1KDM4EALDH1A1MAPT | |
| SCHEMBL28426376 | 0.60 | ESR1 (0.42) | ESR2ESR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838584-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2005-01-04 | — | — | US | disclosed |
| US-20040162304-A1 | Estrogen receptor modulators | MERCK & CO., INC. | 2004-08-19 | — | — | US | disclosed |
| EP-1387821-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002091993-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162304-A1 | Estrogen receptor modulators | ESRRA, GPER1, ESRRB | ESR2 4/4885ESR1 5/4885HSD17B10 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.